Antigen News and Research

RSS

New study may allow scientists to develop screening test for idiopathic pulmonary fibrosis

A simple blood test could predict which patients with the lung-scarring disease known as idiopathic pulmonary fibrosis (IPF) are soon to get far worse, an indicator that could one day influence their treatment, according to researchers at the University of Pittsburgh School of Medicine.

4 Feb 2010

Pall launches PallSep Biotech filtration system

Pall Corporation, a global leader in filtration, separation and purification, has introduced the PallSep Biotech system for the gentle separation of target molecules from complex biotechnology process fluids.

From Pall Corporation 3 Feb 2010

GenSpera’s G-115 anti-cancer drug awarded US patent

GenSpera, Inc. announced that its patent application, entitled “Tumor Activated Prodrugs,” has been issued by the United States Patent and Trademark Office (USPTO) as US Patent 7,635,682. The patent covers the composition and potential uses of G-115, GenSpera’s second anti-cancer drug in development.

2 Feb 2010

Mentor Capital's Cancer Immunotherapy Index: First funding tranche to extend investment closes

Mentor Capital, Inc.'s first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.

2 Feb 2010

Agent-enhanced CT scan plays a supporting role in diagnosing severe cases of H1N1 flu virus

Published reports on the usefulness of CT scans for complicated H1N1 cases have spurred use of these procedures in U.S. hospitals. According to healthcare market research publisher Kalorama Information, this opens up a pathway of diagnostics for physicians and overall is a positive sign not only for the technology but also for companies making chemical agents for procedures.

29 Jan 2010

Inovio Biomedical unveils new clinical-grade, miniaturized electroporation device

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, today unveiled its new clinical-grade, miniaturized electroporation device designed to be an easy-to-use, portable delivery product for DNA vaccines.

28 Jan 2010

TE can be accurately performed in majority of NAFLD patients to exclude advanced fibrosis

Researchers from France and Hong Kong determined that transient elastography (TE), a noninvasive, ultrasonic imaging modality, can be accurately performed in the majority of patients with nonalcoholic fatty liver disease (NAFLD) to exclude advanced fibrosis. Full findings of this study, funded by the Chinese University of Hong Kong, appear in the February issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

27 Jan 2010

Study: PROSTVAC-VF vaccine effective in treating patients with metastatic prostate cancer

In a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine, report researchers at Dana-Farber Cancer Institute and affiliated organizations.

27 Jan 2010

Neoprobe completes license amendment with The Dow Chemical

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it has completed a license amendment with The Dow Chemical Company for a variety of antibodies used in its proprietary surgical oncology system called radioimmunoguided surgery or RIGS®.

27 Jan 2010

Abbott submits Premarket Approval application for the ARCHITECT HIV Ag/Ab Combo assay to FDA

An assay to aid in the early detection of HIV infection may soon be available in the United States. Abbott announced today it has submitted a Premarket Approval application for the ARCHITECT HIV Ag/Ab Combo assay to the U.S. Food and Drug Administration (FDA) for expedited review. Upon approval, the assay is expected to be the first test available in the United States to simultaneously detect the combined presence of HIV antigens (proteins produced by the HIV virus) and antibodies (proteins produced by the body to fight HIV antigens), which would allow for the early detection and ongoing monitoring of the virus.

26 Jan 2010

USPTO issues new patent for Advaxis' intellectual property portfolio

The U.S. Patent and Trademark Office (USPTO) issued today patent 7,635,479, "Compositions and Methods for Enhancing the Immunogenicity of Antigens,” by Dr. Yvonne Paterson, et al, which is assigned to the Trustees of the University of Pennsylvania and licensed to Advaxis, Incorporated (OTCBB: ADXS).

22 Jan 2010

IMUC’s ICT-107 vaccine product candidate targets cancer stem cells

ImmunoCellular Therapeutics today announced the results of a study in which it was shown that certain specific antigens are highly expressed on cancer stem cells (CSCs). This suggests that IMUC’s lead cancer vaccine product candidate ICT-107, which targets those antigens, may effectively target not only the cells that make up the bulk of certain cancerous tumors, but also the CSCs that are widely believed to give rise to them and cause their recurrence.

21 Jan 2010

QuantRx Biomedical's developments in genetics-based technology

QuantRx® Biomedical Corporation, a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today provided an update from Chairman and Chief Executive Officer Walter Witoshkin on its involvement in genetics-based personalized medicine and disease prevention.

20 Jan 2010

Media outlets examine efforts to develop malaria vaccines

Scientists have identified a group of proteins they say could form the basis of a malaria vaccine, Australia's ABC News reports. "However, they say more laboratory work and clinical trials need to be done, with a vaccine at least 10 years away," the news service reports (Macey, 1/19).

20 Jan 2010

Babraham Institute research may lead to new means of making purified T cells

Research from the Babraham Institute, reported today in the Journal of Experimental Medicine, provides new insights into how our immune system produces T cells, a type of white blood cell that is an essential part of the body's immune surveillance system for fighting infection. The findings pave the way for a new means of making purified T cells, which gets over one of many hurdles faced in the use of T cells in regenerative medicine and transplantations, and in addition will open up new avenues of research and applications in drug and toxicity testing in industry.

18 Jan 2010

Need for further studies on clinical characteristics of Intrahepatic Cholangiocarcinoma

Incidence of intrahepatic cholangiocarcinoma (ICC) is increasing worldwide and its prognosis is very poor. Thus, further studies on its clinical characteristics for early detection and on surgical treatment for better prognosis are urgently needed.

18 Jan 2010

PATH MVI announces collaboration in development of malaria TBV

The PATH Malaria Vaccine Initiative (MVI) today announced a new collaboration to initiate development toward a vaccine that may eventually help eliminate and eradicate malaria. This collaboration with the Johns Hopkins Bloomberg School of Public Health (JHSPH) and the Sabin Vaccine Institute (Sabin) marks MVI's first investment in transmission-blocking vaccines (TBVs). This vaccine approach aims to stop the malaria parasite from developing in the mosquito, effectively blocking transmission of malaria from mosquitoes to humans. Malaria kills nearly 900,000 people per year, most of them children younger than age five.

18 Jan 2010

Research reveals how cancers shield themselves from immune attack

Melanoma, if not detected in its early stages, transforms into a highly deadly, treatment-resistant cancer. Although the immune system initially responds to melanoma and mounts anti-tumor attacks, these assaults are generally ineffective, allowing more advanced melanomas to win the battle and spread beyond the primary site.

13 Jan 2010

European trial casts doubt over the viability of prostate cancer screening

A large European trial has cast doubt over the viability of prostate cancer screening, concluding that one in eight men receive a positive test result when they do not have the disease.

13 Jan 2010

Media outlets examine U.S. plans for leftover H1N1 vaccine, efforts to keep flu vaccine production on track

After working to ensure the U.S. had access to enough H1N1 (swine flu) vaccine, health officials may now face a new dilemma - a vaccine surplus, the Associated Press reports.

12 Jan 2010

Antigen News and Research

New study may allow scientists to develop screening test for idiopathic pulmonary fibrosis

Pall launches PallSep Biotech filtration system

GenSpera’s G-115 anti-cancer drug awarded US patent

Mentor Capital's Cancer Immunotherapy Index: First funding tranche to extend investment closes

Agent-enhanced CT scan plays a supporting role in diagnosing severe cases of H1N1 flu virus

Inovio Biomedical unveils new clinical-grade, miniaturized electroporation device

TE can be accurately performed in majority of NAFLD patients to exclude advanced fibrosis

Study: PROSTVAC-VF vaccine effective in treating patients with metastatic prostate cancer

Neoprobe completes license amendment with The Dow Chemical

Abbott submits Premarket Approval application for the ARCHITECT HIV Ag/Ab Combo assay to FDA

USPTO issues new patent for Advaxis' intellectual property portfolio

IMUC’s ICT-107 vaccine product candidate targets cancer stem cells

QuantRx Biomedical's developments in genetics-based technology

Media outlets examine efforts to develop malaria vaccines

Babraham Institute research may lead to new means of making purified T cells

Need for further studies on clinical characteristics of Intrahepatic Cholangiocarcinoma

PATH MVI announces collaboration in development of malaria TBV

Research reveals how cancers shield themselves from immune attack

European trial casts doubt over the viability of prostate cancer screening

Media outlets examine U.S. plans for leftover H1N1 vaccine, efforts to keep flu vaccine production on track

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News